Stock Scorer

Cytokinetics Inc (CYTK)

Cytokinetics Inc reported revenue of 28.6M USD for the quarter ending 30 June 2026, down 57.1% from 66.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 28.6M -57.1%
Operating Income Q2 '26 · ending 30 June 2026 -179.2M —
Net Income Q2 '26 · ending 30 June 2026 -198.8M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -159.8M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -164.2M —
Shares Outstanding Q2 '26 · ending 30 June 2026 132.1K +11.5%
EPS Q1 '21 · ending 31 March 2021 -2.02 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 88M-612.3M-785M-534.8M
20242024-12-31 18.5M-536.2M-589.5M-399.8M
20232023-12-31 7.5M-496.2M-526.2M-415.7M
20222022-12-31 94.6M-324.2M-389M-310.9M
20212021-12-31 70.4M-186.3M-215.3M-191.4M
20202020-12-31 55.8M-93.9M-127.3M-2.1M
20192019-12-31 26.9M-98.9M-121.7M-93.5M
20182018-12-31 31.5M-88.9M-106.3M-102.1M
20172017-12-31 13.4M-113.4M-127.8M-104.6M
20162016-12-31 106.4M18.7M16.5M35.4M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3028.6M
Q1 '262026-03-3119.4M
Q4 '252025-12-3117.8M
Q3 '252025-09-301.9M
Q2 '252025-06-3066.8M
Q1 '252025-03-311.6M
Q4 '242024-12-3116.9M
Q3 '242024-09-30463K
Q2 '242024-06-30249K
Q1 '242024-03-31835K
Q4 '232023-12-311.7M
Q3 '232023-09-30378K
Q2 '232023-06-30867K
Q1 '232023-03-314.6M
Q4 '222022-12-312M
Q3 '222022-09-302.5M
Q2 '222022-06-3089M
Q1 '222022-03-311.1M
Q4 '212021-12-3155.6M
Q3 '212021-09-305.4M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-179.2M
Q1 '262026-03-31-183.6M
Q4 '252025-12-31-178.4M
Q3 '252025-09-30-166.8M
Q2 '252025-06-30-111.5M
Q1 '252025-03-31-155.6M
Q4 '242024-12-31-139M
Q3 '242024-09-30-140.8M
Q2 '242024-06-30-130.2M
Q1 '242024-03-31-126.2M
Q4 '232023-12-31-127.4M
Q3 '232023-09-30-122.3M
Q2 '232023-06-30-122M
Q1 '232023-03-31-124.5M
Q4 '222022-12-31-127M
Q3 '222022-09-30-108.4M
Q2 '222022-06-30-10.9M
Q1 '222022-03-31-77.9M
Q4 '212021-12-31-21.7M
Q3 '212021-09-30-69.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-198.8M
Q1 '262026-03-31-206M
Q4 '252025-12-31-183M
Q3 '252025-09-30-306.2M
Q2 '252025-06-30-134.4M
Q1 '252025-03-31-161.4M
Q4 '242024-12-31-150M
Q3 '242024-09-30-160.5M
Q2 '242024-06-30-143.3M
Q1 '242024-03-31-135.6M
Q4 '232023-12-31-136.9M
Q3 '232023-09-30-129.4M
Q2 '232023-06-30-128.6M
Q1 '232023-03-31-131.3M
Q4 '222022-12-31-137.4M
Q3 '222022-09-30-142.3M
Q2 '222022-06-30-19.8M
Q1 '222022-03-31-89.4M
Q4 '212021-12-31-30.6M
Q3 '212021-09-30-76.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-159.8M
Q1 '262026-03-31-145.5M
Q4 '252025-12-31-142.7M
Q3 '252025-09-30-107.5M
Q2 '252025-06-30-128.2M
Q1 '252025-03-31-131.6M
Q4 '242024-12-31-65.6M
Q3 '242024-09-30-101.5M
Q2 '242024-06-30-99.3M
Q1 '242024-03-31-129.5M
Q4 '232023-12-31-74M
Q3 '232023-09-30-96.2M
Q2 '232023-06-30-121.8M
Q1 '232023-03-31-122.3M
Q4 '222022-12-31-98.2M
Q3 '222022-09-30-84M
Q2 '222022-06-30-90.5M
Q1 '222022-03-31-26.8M
Q4 '212021-12-31-44.7M
Q3 '212021-09-30-38.8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-164.2M
Q1 '262026-03-31-151.4M
Q4 '252025-12-31-148.3M
Q3 '252025-09-30-116.9M
Q2 '252025-06-30-132.4M
Q1 '252025-03-31-137.3M
Q4 '242024-12-31-66.9M
Q3 '242024-09-30-102.2M
Q2 '242024-06-30-101.2M
Q1 '242024-03-31-129.5M
Q4 '232023-12-31-74.1M
Q3 '232023-09-30-96.4M
Q2 '232023-06-30-122.5M
Q1 '232023-03-31-122.7M
Q4 '222022-12-31-101.4M
Q3 '222022-09-30-90.4M
Q2 '222022-06-30-91.3M
Q1 '222022-03-31-27.8M
Q4 '212021-12-31-62.5M
Q3 '212021-09-30-54.5M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30132.1K
Q1 '262026-03-31123.3K
Q3 '252025-09-30120K
Q2 '252025-06-30119.5K
Q1 '252025-03-31118.5K
Q3 '242024-09-30117.7K
Q2 '242024-06-30109.2K
Q1 '242024-03-31101.9K
Q3 '232023-09-3096.1K
Q2 '232023-06-3095.8K
Q1 '232023-03-3195.2K
Q3 '222022-09-3093.8K
Q2 '222022-06-3085.7K
Q1 '222022-03-3185K
Q3 '212021-09-3080.3K
Q2 '212021-06-3071.8K
Q3 '172017-09-3053.7M
Q3 '162016-09-3043.2M
Q3 '152015-09-3038.8M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '212021-03-31-2.02
Q4 '202020-12-31-2.02
Q3 '202020-09-30-1.90
Q2 '202020-06-30-2.35
Q1 '202020-03-31-2.23
Q4 '192019-12-31-2.11
Q3 '192019-09-30-2.08
Q2 '192019-06-30-1.98
Q1 '192019-03-31-1.93
Q4 '182018-12-31-1.95
Q3 '182018-09-30-2.24
Q2 '182018-06-30-2.44
Q1 '182018-03-31-2.53
Q4 '172017-12-31-2.59
Q3 '172017-09-30-1.66
Q2 '172017-06-30-0.29
Q1 '172017-03-310.02
Q4 '162016-12-310.33
Q3 '162016-09-30-0.07
Q2 '162016-06-30-1.07